Statement of Principles concerning neoplasm of the pituitary gland (Balance of Probabilities) (No. 71 of 2024)

The Statement organises a small number of legal‑medical concepts that adjudicators use to assess causation for statutory claims. The text repeatedly ties those concepts to statutory terms and to defined technical meanings in its Schedule. The principal concepts are:

• Neoplasm of the pituitary gland, defined in s 7(2): a primary neoplasm arising from pituitary cells, covering anterior and posterior pituitary tumours and pituitary stalk tumours; it also lists excluded tumour types (s 7(2)(a)-(c)). The instrument notes the ICD‑10‑AM codes associated with the condition (s 7(3)-(4)) but stresses that the statutory meaning is the textual definition (s 7(3)).

• Death from neoplasm of the pituitary gland, which extends to death from a terminal event or condition that the neoplasm contributed to (s 7(5)); “terminal event” is given a closed list of examples in Schedule 1 (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

• Relevant service, which is a defined term in the Schedule and includes eligible war service, defence service, and peacetime service under the MRCA (Schedule 1). The Statement operates only where a claimant’s service meets one of those categories (s 5 and Schedule 1).

• The standard of proof: although the statutory phrase “Balance of Probabilities” is in the title, the instrument expressly states that, on the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that “it is more probable than not” that the condition can be related to relevant service (s 8). That language embeds the civil standard of proof into the RMA’s determination of the Statement itself.

• Mandatory factors that can support a causal connection, set out in s 9. They are narrow and specific: (1) prior bilateral adrenalectomy for Cushing disease before clinical worsening of a corticotroph pituitary adenoma; (2) use of specified GnRH agonists at the time of pituitary apoplexy of a pre‑existing pituitary adenoma (four drugs listed); (3) administration of specified hormones in a dynamic endocrine test within four days before pituitary apoplexy (four hormones listed); and (4) inability to obtain appropriate clinical management for the neoplasm before clinical worsening.

• Clinical worsening and pituitary apoplexy are defined descriptively in the notes to s 9: pituitary apoplexy is described as a clinical worsening of a pre‑existing adenoma, characterised by sudden loss of blood supply, tissue necrosis and loss of function (s 9 notes). Section 10(2) then limits the application of clinical‑worsening factors to cases where the neoplasm was suffered before or during, but did not arise out of, the person’s relevant service.

• Cross‑statement interaction: where a s 9 factor refers to an injury or disease that is covered by another Statement of Principles made under subsection 196B(3) of the VEA, the factors in that other Statement apply according to their terms (s 11).

These concepts operate as a filter: a claimant must show at least one of the listed factors (s 9) and link that factor to relevant service (s 10(1)). The Statement frames medical events and interventions (surgeries, drugs, dynamic tests) as the triggers that establish the necessary link on the balance of probabilities, and it creates a procedural rule for adjudicators to accept those specified relationships as sufficient, where proved, to meet the Statement.

The instrument directly affects three categories of persons and bodies identified in the text.

1. Claimants (veterans and members of the Forces) who lodge claims to which section 120B of the VEA or section 339 of the MRCA applies (s 5). The Statement sets out the conditions under which neoplasm of the pituitary gland or death from it can be found to be connected with a person’s relevant service. In practice, that narrows the universe of claimants who can succeed on causation to those who can establish one or more of the defined factors in s 9 and the service connection required by s 10(1).

2. Decision‑makers administering the VEA and the MRCA. Although the Statement does not name a decision maker, it is made under s 196B(3) of the VEA and expressly applies to claims falling under specified provisions of the VEA and MRCA (s 5). Therefore, the officials or statutory decision‑makers who determine entitlement under those Acts will apply this instrument as the basis for causation in respect of neoplasm of the pituitary gland; the RMA’s stated view on the medical evidence (s 8) informs the evidentiary frame applied by those decision‑makers.

3. Medical practitioners and treating clinicians. The factors in s 9 refer to specific clinical events, procedures and medications: bilateral adrenalectomy, GnRH agonists (goserelin, leuprorelin/leuprolide, nafarelin, triptorelin), dynamic endocrine tests using GnRH, GHRH, TRH or CRH within specified timing before pituitary apoplexy, and the inability to obtain appropriate clinical management before clinical worsening (s 9). The presence, timing and documentation of those clinical events will materially affect whether a claim meets the Statement. Medical records, operative reports, medication charts, endocrinology test records and correspondence about access to care will be the primary source material relied upon.

Indirectly affected parties include entities responsible for record‑keeping and evidence provision such as hospitals, pharmacists and specialists, because the practical ability of a claimant to prove one of the s 9 factors depends on the availability and quality of contemporaneous medical documentation. The instrument also affects continuity of adjudication because it repeals the previous Statement No. 54 of 2015 (s 4), so claims and decisions after the commencement date (s 2) are governed by the new text.

Who pays: the Statement itself does not list benefit amounts or payment mechanisms, but it governs entitlement findings under specified provisions of the VEA and MRCA (s 5); therefore, an established causal link under this Statement will be part of the legal basis on which administrative payments and entitlements under those Acts are awarded or refused.

Who decides: the Repatriation Medical Authority made the Statement (s 3 and the signature block); decision‑makers under the VEA and MRCA apply it to claims (s 5). The RMA’s view on the medical evidence is explicit in s 8.

The instrument does not create duties in the manner of an administrative regulation imposing new procedural obligations on private parties; rather, it prescribes the legal criteria that must be met for a causal connection between neoplasm of the pituitary gland (or death from it) and relevant service. Still, it creates concrete legal rights and functional tests used by decision‑makers.

Rights established by the Statement

• A right to have a claim for neoplasm of the pituitary gland or death from it considered as connected with relevant service where the claimant proves, on the balance of probabilities, at least one of the factors in s 9 and relates that factor to their relevant service (s 9; s 10(1)). The Statement therefore confers an evidentiary route for entitlement under the VEA and MRCA provisions referenced in s 5.

Tests and functional duties on decision‑makers

• Decision‑makers must apply the textual definition of neoplasm in s 7(2) when determining whether the claimant’s disease fits within the Statement, notwithstanding that ICD‑10‑AM codes are noted (s 7(3)). This imposes a duty to match the claimant’s clinical diagnosis against the precise statutory definition and listed exclusions.

• Decision‑makers must accept that the RMA has formed the view that, on the available medical‑scientific evidence, it is more probable than not that the condition can be related to relevant service (s 8). That is the RMA’s evidentiary assessment supporting the Statement; the functional duty on adjudicators is to apply the Statement as the authoritative statement of the medical relationships it contains.

• Decision‑makers must require that at least one factor in s 9 exist and be related to relevant service (s 9; s 10(1)). For factors entailing “clinical worsening” or pituitary apoplexy, s 10(2) constrains application to cases where the neoplasm was suffered or contracted before or during (but did not arise out of) relevant service; decision‑makers must therefore assess both the timing of disease onset relative to service and whether the disease arose out of service.

• Where a factor in s 9 refers to an injury or disease already covered by another Statement of Principles, the decision‑maker must apply the factors in that other Statement as in force from time to time (s 11). This imposes an interpretive duty to cross‑check and potentially integrate other Statements, following their terms.

Procedural implications for claimants (practical duties)

• To make effective use of the Statement, claimants bear the practical obligation of adducing evidence that one of the precise factors in s 9 existed and of connecting that factor to their relevant service (s 9; s 10(1)). The Statement itself does not prescribe the form of evidence; however, because the factors are procedural and medically time‑bound (for example, timing of dynamic endocrine testing within four days before apoplexy in s 9(3)), claimants must present medical records, test reports, medication records and service records that establish dates and causal sequences.

Limitations on rights and duties

• The Statement narrows potential rights by listing explicit exclusions in s 7(2)(c). If the claimant’s tumour falls within one of those excluded categories, the claimant cannot rely on this Statement for connection. Similarly, the clinical‑worsening factors do not apply where the neoplasm arose out of relevant service (s 10(2)).

In short, the Statement does not itself create payments or procedural entitlements; it creates the legal standard and prescribed evidentiary pathways that determine whether claims made under the specified sections of the VEA and MRCA will be accepted as service‑connected for neoplasm of the pituitary gland or death from it. Decision‑makers and claimants have reciprocal duties: decision‑makers must apply the textual tests and cross‑references; claimants must produce the specific, time‑stamped clinical evidence that the Statement requires.

The Statement is a determinative medical instrument under the statutory framework of the VEA and is not a penal statute. It does not create criminal or civil penalties, nor does it prescribe enforcement mechanisms such as fines or sanctions for non‑compliance with its terms. The instrument’s legal effect is to set the causal criteria used in deciding entitlement under relevant provisions of the VEA and MRCA (s 5).

Enforcement in this context means administrative application by decision‑makers:

• Administrative effect: The Statement will be applied by the decision‑maker who determines claims under section 120B of the VEA or section 339 of the MRCA (s 5). The instrument shapes the outcome of claim adjudication; success or failure of a claim will carry consequences under the VEA and MRCA (for example, benefits or denial), but those consequences arise from the principal Acts and their administrative schemes rather than from this Statement itself.

• No sanctions in the instrument: The text contains no enforcement provisions, penalty schedules, civil remedies or criminal offences. It does not establish adverse administrative sanctions for medical practitioners, hospitals or other third parties for failing to record or provide evidence; it simply prescribes the factors that must be shown for a causal finding.

• Repeal and replacement as an administrative control: The instrument repeals the prior Statement No. 54 of 2015 (s 4). The practical enforcement implication is that, on commencement (s 2), adjudicators must apply the new Statement rather than the repealed one. There is no transitional clause in the instrument describing how pending claims are to be treated; the absence of transitional rules is itself an administrative implementation matter that may affect outcomes in individual cases.

Potential enforcement or review mechanisms outside the instrument: while the Statement does not create penalties, administrative decisions that apply the Statement are likely subject to the review and appeal processes provided under the VEA and the MRCA, and to any general administrative law remedies (judicial review) that apply to decisions made under those Acts. The instrument, however, does not itself specify or modify those review rights.

In sum, the Statement functions as an evidentiary rule‑set rather than an enforcement instrument. It enforces nothing by punishment; its operative force is to change the threshold and routes by which claimants secure or fail entitlements under other legislation.

The Statement is explicitly made under subsection 196B(3) of the VEA (s 3) and expressly applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (s 5). Its relationship to the broader legislative framework is therefore primarily as an evidentiary annex used for causation findings under two other Acts.

Cross‑instrument interaction mandated by the text

• Primary Acts: The instrument is subordinate to the VEA and functions as a medical determination under the VEA’s statutory mechanism. It does not stand alone; its practical operation is to determine whether a condition is treatable as related to “relevant service” for the purposes of the named provisions in the VEA and MRCA (s 5). The Statement does not alter or set rates of benefit, procedural appeal rights or other substantive rules contained in those Acts; it supplies medical causation criteria for use in adjudication.

• Other Statements of Principles: Section 11 provides a specific interaction rule: if a factor in s 9 refers to an injury or disease covered by another Statement of Principles made under subsection 196B(3) of the VEA, then the factors in that other Statement apply according to their terms. This creates a networked structure in which Statements link to each other; decision‑makers must apply the other Statement’s factors as in force, which may incorporate further medical definitions or temporal rules.

Classification and coding interaction

• ICD‑10‑AM codes are referenced in s 7(3)-(4): while neoplasm of the pituitary gland is associated with ICD codes C75.1, D35.2 and D44.3, subsection 7(3) clarifies that, for applying this Statement, the meaning is the textual definition in s 7(2). This is a formal rule that prevents mechanical reliance on ICD coding alone; adjudicators must compare the claimant’s clinical diagnosis against the statutory wording rather than merely the code.

Temporal and causation boundaries

• The Statement defines a specific temporal and causal relationship between clinical events and relevant service. Section 10(2) restricts the reach of the “clinical worsening” aspects of s 9 to cases where the neoplasm was “suffered or contracted before or during (but did not arise out of) the person's relevant service.” That is a statutory interface between the onset of disease, the claimant’s service, and the precise application of clinical‑worsening factors, which adjudicators must interpret in the context of the VEA and MRCA provisions.

Absence of amendment or transitional provisions

• The instrument repeals the prior Statement (s 4) but does not include express transitional provisions or savings clauses for decisions made or commenced under the earlier Statement. The absence of such clauses means that the new Statement will govern claims from its commencement date (s 2), but the instrument leaves the precise handling of pending matters to the administrative processes of the VEA and MRCA decision‑makers and to any overarching provisions in those Acts.

Implications for evidence law and administrative review

• The Statement does not change general evidentiary rules, appeal rights, or procedures under the VEA or MRCA. However, by defining specific medical pathways that satisfy causation, it will materially affect the admissibility and probative use of clinical records, operative reports, medication histories and service records in administrative decision‑making and any subsequent reviews or appeals under the parent statutes.

In short, the Statement operates as a specialised, authoritative medical annex to the causation and entitlement architecture of the VEA and MRCA. It instructs decision‑makers how to treat certain clinical events and diagnostic categories when applying the VEA and MRCA, while explicitly deferring to other Statements of Principles where references overlap (s 11) and clarifying the role of ICD coding (s 7(3)).

This instrument is numbered No. 71 of 2024 and is dated 20 August 2024. It commences on 24 September 2024 (s 2). The sole amendment action recorded within the instrument is the repeal of the previous Statement of Principles concerning neoplasm of the pituitary gland No. 54 of 2015 (Federal Register No. F2015L00260), itself a Statement made under subsection 196B(3) of the VEA (s 4). The new Statement therefore replaces that earlier instrument in the statutory schedule of Statements of Principles once it commences.

What the instrument records about its provenance

• Authority: The instrument is expressly made under subsection 196B(3) of the VEA (s 3). The signature block indicates it was determined by the Repatriation Medical Authority and signed by the Chairperson on behalf of the Authority (cover page and s 3). The instrument also contains the standard internal cross‑references and a Schedule (Schedule 1) defining terms used in the text.

Not recorded within the instrument

• The instrument does not contain a legislative history prior to No. 71 of 2024 aside from the fact it repeals No. 54 of 2015. There are no amendments recorded to the new text itself within the document, and there are no transitional provisions or savings clauses about how pending claims should be treated relative to the repeal (s 4). No subsequent amendment dates or variation notes are included.

Practical consequences of the amendment action

• Repeal of the prior Statement means that the precise factors listed in s 9 of the new Statement, and the definitions in s 7 and Schedule 1, will be the operative tests for causation from the commencement date (s 2). Because the instrument contains no transitional rule, decision‑makers will need to apply established administrative principles or relevant provisions of the VEA/MRCA to determine treatment of claims that were in process at commencement, unless those parent Acts provide otherwise.

Recordation and public availability

• The instrument includes the date and the formal identification number but no further contextual material such as an explanatory memorandum or notes on the medical evidence relied upon. Section 8 states that the RMA determined its view on the basis of “sound medical‑scientific evidence available,” but the Statement does not reproduce that evidence or an explanation of how it supports the specific factors. Any additional record of the medical evidence or RMA material would need to be sought from RMA releases or supporting documents outside the instrument itself; the instrument contains no annexed evidentiary material.

The instrument itself does not record any litigation history, judicial decisions, or administrative appeals related to this Statement of Principles. No cases, appeals or judicial reviews are named or described in the text. The document therefore provides no direct record of prior challenges to the Statement, to the RMA’s determinations, or to decisions by claim‑determining bodies applying earlier Statements.

Matters the instrument does supply that bear on potential disputes

• The Statement asserts that the Repatriation Medical Authority formed its view “on the sound medical‑scientific evidence available” and concludes that “it is more probable than not” that neoplasm of the pituitary gland can be related to relevant service (s 8). That statement evidences an evidentiary basis for the Statement but does not include or cite the underlying studies, data or reports. The absence of the supporting medical evidence in the instrument may be relevant in administrative review or judicial review proceedings where the sufficiency of the RMA’s reasoning or evidence is contested; the instrument itself, however, does not document the evidence.

• The instrument repeals an earlier Statement (s 4). Where administrative decisions made under the old Statement are revisited after the new Statement’s commencement, that change in legal criteria could give rise to disputes about transitional application, retrospective effect, or the proper treatment of pending claims. The Statement contains no transitional provisions; any litigation over such matters would depend on the parent Acts (VEA and MRCA) and general administrative law principles, not on content within this Statement.

Potential grounds for challenge (eclectic observations based on the instrument’s contents)

• Factual sufficiency: Because the Statement sets out specific medical scenarios and temporal relationships (s 9 and s 10), claimants denied under those tests may seek merits review under the VEA/MRCA schemes or judicial review if they can show the decision‑maker misapplied the statutory tests or failed to consider relevant evidence. The instrument supplies the criteria but not the factual evidence, so disputes will likely centre on weight and interpretation of medical records, the timing of interventions, and whether the clinical descriptions in the notes align with the claimant’s presentation.

• Interaction with other Statements: Section 11 requires application of other Statements when a factor refers to another disease covered elsewhere. Litigation or review may arise where there is ambiguity in applying multiple linked Statements or where contemporaneous amendments place different requirements on overlapping conditions.

What the Statement does not supply

• The instrument does not include any judicial consideration of its terms, nor does it summarise previous litigation. Therefore, anyone assessing litigation risk or precedential authority will need to search the VEA/MRCA case law and administrative tribunal decisions separately; the Statement provides the operative criteria but no record of how tribunals or courts have treated similar determinations.

In short, the instrument contains no internal litigation history; it provides criteria that will be applied in claims, and disputes may arise in practice about application, sufficiency of evidence and transitional handling, but the document itself does not narrate or record any adjudicative outcomes.

The Statement contains a set of precise definitions and narrowly framed factors; practitioners and claimants should be alert to the following points where an apparently small factual difference can be dispositive.

Definition vs coding: textual definition controls

• While s 7(3) notes ICD‑10‑AM codes (C75.1, D35.2, D44.3) associated with pituitary neoplasms, subsection 7(3) explicitly states that “in applying this Statement of Principles the meaning of neoplasm of the pituitary gland is that given in subsection (2).” Do not rely solely on an ICD code recorded in hospital data; the tumour must meet the textual elements (s 7(2)), including the included sites and the exclusions listed in s 7(2)(c).

Narrow inclusions and express exclusions

• The text includes anterior pituitary tumours, posterior pituitary tumours and tumours of the pituitary stalk (s 7(2)(b)). It expressly excludes soft tissue sarcoma, carcinoid tumour, non‑Hodgkin lymphoma, Hodgkin lymphoma, tumours of the hypothalamus, tumours of the sella turcica and tumours of the diaphragma sellae (s 7(2)(c)). If a claimant’s histopathology or imaging report indicates one of those excluded entities or a tumour primarily arising from an excluded anatomical site, the Statement will not apply.

Strict and specific factors (s 9)

• The claimant must show at least one of the factors listed in s 9. Those factors are tightly framed:
  • s 9(1) requires bilateral adrenalectomy for Cushing syndrome due to a corticotroph pituitary adenoma before clinical worsening of that adenoma. Timing and the precise indication (Cushing disease due to corticotroph adenoma) are essential.
  • s 9(2) permits connection where a claimant was taking one of four named GnRH agonists “at the time of pituitary apoplexy of a pre‑existing pituitary adenoma.” The drug and the concurrence of apoplexy matter.
  • s 9(3) requires one of four hormones to have been used as part of a dynamic endocrine test within four days before pituitary apoplexy. The four‑day window is a strict temporal requirement.
  • s 9(4) enables a finding where there was “inability to obtain appropriate clinical management” before clinical worsening; that factor is inherently fact‑sensitive and will require evidence of attempts to obtain care and that such inability materially contributed to worsening.

Clinical worsening vs arising out of service

• Section 10(2) contains a critical restriction: the “clinical worsening” aspects of s 9 apply only where the person’s neoplasm “was suffered or contracted before or during (but did not arise out of) the person's relevant service.” If the tumour arose out of the person’s relevant service, then the clinical‑worsening pathway in s 9 does not operate. Practically, this means that claimants and decision‑makers must distinguish between the initial onset (suffered or contracted) and whether the disease “arose out of” service. That distinction is central to whether the clinical‑worsening factors can be invoked.

Timing precision

• Several factors impose short windows (for example, the four days in s 9(3) and “at the time of” in s 9(2)) or sequencing requirements (for example, bilateral adrenalectomy before clinical worsening in s 9(1)). Medical and service records must therefore establish precise dates and sequences; vague or inconsistent records risk failing the specific factors.

Cross‑reference trap

• If a s 9 factor refers to an injury or disease covered by another Statement, s 11 requires application of that other Statement’s factors “as in force from time to time.” Practitioners must identify and apply the current text of any linked Statements; an older version or partial citation may be insufficient.

Absence of transitional provisions

• The instrument repeals the earlier Statement (s 4) but contains no transitional or savings clauses. Practitioners should therefore not assume pending claims will be treated under the old criteria; administrative practice or the parent Acts will govern transitional treatment. The lack of a transitional rule is a procedural risk for claimants with events that straddle the repeal/commencement dates.

“Death from” includes terminal events

• For death claims, s 7(5) includes deaths from terminal events or conditions that were contributed to by the neoplasm. The Schedule defines “terminal event” by example (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). A death certificate listing one of these proximate causes may be connected to the neoplasm if causal contribution can be supported, but practitioners must assemble clinical evidence of contribution; a listed terminal event alone is not automatically the same as death “from” the neoplasm without evidence of contribution.

Evidence not included in the Statement

• Section 8 asserts the RMA’s view is based on “sound medical‑scientific evidence available” but the Statement does not include that evidence. Challenges about sufficiency or interpretation of the medical basis will require obtaining the RMA’s supporting materials or the medical literature outside the instrument.

Beware of “arose out of” wording

• The instrument uses “suffered or contracted before or during (but did not arise out of) the person's relevant service” (s 10(2)) in a way that can be misunderstood. This is not just a timing clause; it excludes some clinical‑worsening pathways where the initial disease is itself a service onset. Accurate factual positioning of onset relative to service is therefore crucial.

In practice, small differences in diagnostic wording, drug names, dates, or anatomical descriptions will determine whether the Statement applies. The instrument privileges specificity over breadth; legal and medical practitioners should treat every item in s 7, s 9 and s 10 as potentially dispositive.

Compliance in this context means assembling and presenting the factual and medical material necessary for a decision‑maker under the VEA or MRCA to find, on the balance of probabilities, that the claimant’s neoplasm of the pituitary gland (or death from it) is connected with their relevant service under the terms of this Statement. The Statement itself does not prescribe procedural forms, but it imposes clear evidentiary demands through its definitions and factors. Practitioners should follow the steps below, citing the relevant sections of the instrument:

1. Confirm that the claim falls within the Statement’s application

• Verify that the claim is one to which section 120B of the VEA or section 339 of the MRCA applies (s 5). If the claim is not within those statutory gateways, the Statement is not the operative determinative instrument.

2. Match the clinical diagnosis to the statutory definition

• Compare histopathology, imaging, specialist diagnosis and operative notes against the textual definition in s 7(2). Ensure that the tumour is a primary neoplasm arising from pituitary cells, and confirm whether it is located in the anterior pituitary, posterior pituitary or pituitary stalk. If the tumour is described as one of the excluded entities or sites listed in s 7(2)(c), the Statement will not apply.

3. Establish the precise factor(s) in s 9 relied upon

• Determine which one or more of the s 9 factors is relevant to the claimant’s case and collect documentary proof:
  • For s 9(1): obtain operative reports, surgical discharge summaries and endocrinology notes showing bilateral adrenalectomy, the indication as Cushing syndrome due to a corticotroph pituitary adenoma, and timing relative to any documented clinical worsening. Note the Statement’s note definitions of bilateral adrenalectomy and Cushing disease (s 9 notes).
  • For s 9(2): procure contemporaneous medication charts, oncology/endocrinology prescriptions, specialist letters and hospital records that list one of the four named GnRH agonists (goserelin; leuprorelin/leuprolide; nafarelin; triptorelin) and that the medication was being taken “at the time of” a documented pituitary apoplexy. Also collect records demonstrating the apoplexy event (imaging, acute neurosurgical notes).
  • For s 9(3): assemble records of the dynamic endocrine test, the hormones administered (GnRH, GHRH, TRH, CRH), the test date and precise timing of any subsequent pituitary apoplexy. The four‑day window is binding.
  • For s 9(4): compile evidence demonstrating attempts to obtain “appropriate clinical management” (referral letters, appointment requests, correspondence, waitlist evidence, refusal letters) and documentation of subsequent clinical worsening tied to lack of appropriate care.

4. Demonstrate the relationship to relevant service

• Under s 10(1), any s 9 factor must be related to the person’s relevant service. Collect service records, enlistment documents, deployment records and other official materials evidencing the dates and nature of the claimant’s eligible war service, defence service or peacetime service under MRCA (Schedule 1 definition of “relevant service”).

5. Address the clinical‑worsening temporal rule

• If relying on clinical‑worsening factors, confirm whether the neoplasm was “suffered or contracted before or during (but did not arise out of) the person's relevant service” (s 10(2)). Prepare medical chronology and expert opinion to establish onset dates, and to distinguish “suffered or contracted” from “arose out of” service. If the tumour arose out of service, the clinical‑worsening pathway in s 9 may not be available.

6. Use linked Statements where necessary

• If a s 9 factor refers to an injury or disease covered by another Statement of Principles, identify that Statement and apply its factors as they are current at the time of decision (s 11). Obtain and include the other Statement text and any relevant medical definitions it contains.

7. Link terminal event evidence for death claims

• For death claims, assemble the death certificate, hospital summary, causes of death, and clinical evidence showing contribution by the neoplasm to the terminal event (s 7(5) and Schedule 1 definition of “terminal event”). Demonstrate causal contribution rather than merely the presence of a listed terminal event.

8. Provide expert medical opinion where the factual nexus is complex

• Given the technical nature of pituitary pathology and the narrow temporal requirements (for example the four‑day window in s 9(3) and the “at the time of” language in s 9(2)), contemporaneous expert endocrinology or neurosurgery opinions that tie the medical records to the statutory tests will be important. The Statement itself does not specify the required form of opinion evidence, but decision‑makers will need clear medical reasoning to accept that the precise s 9 conditions are met.

9. Ensure documentation is precise and date‑stamped

• The Statement’s factors are sensitive to dates and sequencing. Make sure medication records, operative notes, imaging reports, test logs and appointment records are included, with dates and times where possible. Vague or undated entries will be harder to reconcile with the Statement’s strict temporal criteria.

10. Anticipate the coding issue

• Do not rely on ICD‑10‑AM coding alone to show the presence of a pituitary neoplasm (s 7(3)). Use the clinical narrative, histology and imaging to meet the textual definition.

11. Prepare for cross‑checking by decision‑makers

• Decision‑makers will compare the evidence against s 7-s 10 and may consult other Statements under s 11. Be ready to address questions about whether the disease fits the statutory definition, whether the factor actually occurred, and whether it is related to relevant service.

12. Consider timing relative to repeal/commencement

• The Statement commences on 24 September 2024 and repeals the 2015 Statement (s 2-4). For claims with events near the repeal/commencement date, document timelines carefully and enquire whether the decision‑maker will treat any pending matters under the prior Statement or the new one; the instrument contains no transitional provision within its text.

In practical terms, compliance is evidence management. The Statement is directive and narrow; success in claims turns on assembling authoritative, date‑specific medical and service records and, where required, expert opinion tailored to the statutory factors and temporal rules set out in s 7 through s 11.